FDA lifts Johnson & Johnson COVID-19 vaccine pause following security assessment

Federal well being officers lifted an 11-day pause on use of the Johnson & Johnson COVID-19 vaccine on Friday following a assessment and the advice of a panel of specialists who decided it met security requirements regardless of uncommon situations of extreme blood clots.

The Meals and Drug Administration and the Facilities Illness Management and Prevention lifted the pause shortly after a CDC advisory panel really helpful a resumption of its use. The panel really helpful inclusion of language warning the general public of a danger of blood clots upon receiving the single-dose vaccine.

“We now have concluded that the identified and potential advantages of the Janssen COVID-19 Vaccine outweigh its identified and potential dangers in people 18 years of age and older,” Performing FDA Commissioner Janet Woodcock stated in an announcement. “We’re assured that this vaccine continues to fulfill our requirements for security, effectiveness and high quality.”

Well being officers paused the rollout of the Johnson & Johnson vaccine on April 13 in response to 6 reported circumstances of thrombosis with thrombocytopenia syndrome (TTS). On the time, the FDA stated it had really helpful a pause and subsequent security assessment out of an abundance of warning.

The FDA and CDC stated they’ve recognized a complete of 15 circumstances amongst practically eight million recipients, all of which occurred in ladies between ages 18 and 59. Three of the ladies died and 7 stay hospitalized. Officers stated signs related to the blood clots appeared between six and 15 days after vaccination.

“Presently, the obtainable information counsel that the prospect of TTS occurring may be very low, however the FDA and CDC will stay vigilant in persevering with to analyze this danger,” the companies stated in a press launch.

European regulators reached an analogous choice earlier this week and allowed the rollout of the Johnson & Johnson vaccine to renew.


Johnson & Johnson stated it was “grateful to the Advisory Committee and its medical specialists for the rigorous analysis of our COVID-19 vaccine.

“The Committee’s suggestion is a necessary step towards persevering with urgently wanted vaccinations in a protected method for hundreds of thousands of individuals within the U.S,” the corporate stated in an announcement. “As the worldwide pandemic continues to devastate communities world wide, we consider a single-shot, simply transportable COVID-19 vaccine with demonstrated safety towards a number of variants might help defend the well being and security of individuals all over the place.”

Leave a Reply

Your email address will not be published. Required fields are marked *